Search results
Showing 61 to 75 of 128 results for epilepsy
Transcranial magnetic stimulation for treating and preventing migraine (HTG330)
Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.
temazepam. Benzodiazepines can also be used for other conditions, such as epilepsy. Talk to your healthcare professional if this applies...
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women and pregnant trans men and non-binary people whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Show all sections
Sections for NG195
- Overview
- Using this guideline
- Information and support for parents and carers
- Prevention and risk reduction
- Risk factors and clinical indicators: early-onset neonatal infection
- Risk factors and clinical indicators: late-onset neonatal infection
- Investigations before starting antibiotics for early-onset or late-onset neonatal infection
- Principles around use of antibiotics for early-onset or late-onset neonatal infection
Awaiting development Reference number: GID-TA10519 Expected publication date: TBC
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer term after starting...
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
Antisocial behaviour and conduct disorders in children and young people (QS59)
This quality standard covers recognising and managing antisocial behaviour and conduct disorders in children and young people. It describes high-quality care in priority areas for improvement.
View quality statements for QS59Show all sections
Sections for QS59
- Quality statements
- Quality statement 1: Early intervention
- Quality statement 2: Comprehensive assessment
- Quality statement 3: Improving access to services
- Quality statement 4: Parent or carer training
- Quality statement 5: Multimodal interventions
- Quality statement 6: Monitoring adverse effects of pharmacological interventions
- Update information
This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS115Show all sections
Sections for QS115
- Quality statements
- Quality statement 1: Valproate
- Quality statement 2: Pre-conception information
- Quality statement 3: Information for pregnant women
- Quality statement 4: Asking about mental health and wellbeing
- Quality statement 5: Comprehensive mental health assessment
- Quality statement 6: Psychological interventions
- Quality statement 7 (developmental): Specialist multidisciplinary perinatal mental health services
cognitive) and behavioural outcomes in children born to women and girls with epilepsy (these should be undertaken on a long-term basis...
Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS51Show all sections
Sections for QS51
- Quality statements
- Quality statement 1: Diagnostic assessment by an autism team
- Quality statement 2: Assessment and diagnosis
- Quality statement 3: Personalised plan
- Quality statement 4: Coordination of care and support
- Quality statement 5: Treating the core features of autism: psychosocial interventions
- Quality statement 6: Treating the core features of autism: medication
- Quality statement 7: Assessing possible triggers for behaviour that challenges